Nutritional supplements

ABSTRACT

The present disclosure relates to novel nutritional methods and compositions containing essential fatty acids which optimize embryonic, fetal and child neurological development and provide improved nutritional support for women prior to and during lactation. Further the methods and compositions improve gestational length and birth weight. The nutritional methods and compositions are also intended for use by women to optimize infant neurological development and provide improved nutritional support for women prior to, during and after lactation.

CROSS-REFERENCE TO RELATED APPLICATION

This application is a continuation application of U.S. patentapplication Ser. No. 10/457,647, filed Jun. 10, 2003; said applicationbeing a continuation-in-part of U.S. patent application Ser. No.09/885,158, filed Jun. 21, 2001 now issued as U.S. Pat. No. 6,576,666;said application being a continuation application of U.S. patentapplication Ser. No. 09/323,159, filed Jun. 1, 1999 now U.S. Pat. No.6,258,846, the entire contents of which are hereby incorporated byreference in their entirety.

BACKGROUND OF INVENTION

The present invention is directed to novel methods for administeringcompositions containing essential fatty acids for use by pregnant and/orlactating women to optimize infant neurological development, length ofgestation, and birth weight and to provide improved nutritional supportfor women prior to, during and after lactation. Further, the inventionis also directed to methods for prevention and treatment of essentialfatty acid deficiencies and conditions related or derived therefrom.

Essential fatty acids (EFAs) are important for all humans in general,and women specifically. Failure to ingest the appropriate amount ofessential fats daily may result in improper digestion, which in turn maycause inadequate absorption of other nutritional factors, includingvitamins and minerals.

Additionally, the body derives its energy from triglycerides, a moleculeof glycerol with three fatty acids attached. Stored fatty acids supportbodily functions, and are especially important when individuals arebetween meals or must go without food. Furthermore, the body cannotproduce all the necessary fatty acids it requires. An example of suchare both linolenic and linoleic acids. Thus a failure in the intake ofthe proper amount of EFAs can have wide ranging negative implications.Furthermore, insufficient daily intake of EFAs can lead to variouslevels of failure in a woman's reproductive system.

For this reason, it is especially important in the case of women who arepregnant or breast feeding or plan to become pregnant or plan to breastfeed that methods of nutritional supplementation of dietary compositionscontaining EFAs be developed.

All major fatty acid classes were altered in the pregnant state. Ofthese differences in polymorphonuclear leukocytes, oleic acid andαa-linolenic acid have been shown to significantly increase (13 and 26%,respectively) and stearic acid and arachidonic acid (AA) has been shownto significantly decrease (8 and 30%, respectively). This may suggestthat attenuated PMN function in pregnancy may originate from a reductionin the available pool of cellular fatty acids. Furthermore, thisreduction arises as a direct result of a pregnancy-induced shift incirculating fatty acids from polyunsaturated to monounsaturated forms.Clin Diagn Lab Immunol. July 1999; 6 (4): 587-593. These shifts incirculating EFAs, have been implicated in low birth weight, shortengestation and in the occurrence of birth defects.

Due to a new born infant's high growth rate and nutritionally dependentstate upon the mother, EFAs in the mother's diet continue to beimportant after birth especially if the mother is to breast feed.

At some time prior to the end of pregnancy, pregnant women face thedecision of whether or not to breast-feed their infants. It is estimatedthat over 50% of all mothers choose to breast-feed their infants. SeeThe Merck Manual, 185:1929-1931 (16^(th)ed. 1992).

Furthermore, the number of women deciding to breast-feed appears to beon the increase, particularly in higher socioeconomic groups. Id. Mostexperts would agree that this increase is very desirable in view of thenumerous recognized nutritional benefits for developing infants whichaccompany their consumption of human milk. Because of the nutritionalbenefits for infants, many health care providers and dietitians believebreast-feeding is sufficiently important to warrant that every effort bemade to breast-feed, even if only for a short time. See Whitney et al.,Understanding Nutrition, 493-504 (6th ed. 1993).

Moreover, in addition to the nutritional benefits of breast-feeding,many women simply want to breast-feed their infants for emotional orpsychological reasons. However, regardless of a woman's underlyingreasons for breast-feeding, her nutritional status is implicated in thedecision of whether to breast-feed her child. For example, a nutritionaldeficiency in a woman may severely limit the quantity of breast milkwhich is produced or, in some cases, entirely prevent lactation fromoccurring.

Generally speaking, the nutritional benefits of breast-feeding stem fromthe unique nutrient composition and protective factors present in breastmilk which promote infant health and development. Id. at 494. Forexample, breast milk generally contains all of the vitamins required forinfant development, with the possible exception of vitamin D. Id. at500. Further, breast milk is an abundant source of minerals and, moreimportantly, some minerals are present in breast milk in highlydesirable ratios (e.g., the 2-to-1 ratio of calcium to phosphorus inbreast milk is ideal for the absorption of calcium). Id. Breast milkalso contains invaluable immunological agents, including antiviralagents such as immunoglobulins, and antibacterial agents such aslactoferrin.

In addition to the above discussed vitamins, minerals and immunologicalagents, breast milk also contains various “energy nutrients.” Forexample, breast milk contains lactose which is the carbohydrate presentin breast milk and which facilitates calcium absorption. Id. Arelatively small amount of protein, primarily in the form ofalpha-lactalbumin, is also present in breast milk, thus placing lessstress on the infant's immature kidneys. Id. Breast milk additionallycontains fat along with fat-digesting enzymes. Id. Linoleic acid, afatty acid, is found in large quantities in breast milk. Id.

The presence of EFAs in breast milk is significant for various reasons,as described below. Because the body derives most of its energy fromstored triglycerides, and the body cannot make all the EFAs it requires,for example linoleic acid or linolenic acid, these indispensable EFAsmust be supplied through the infant's food food. Again, EFAs areimportant for the developing brain, immunological system andcardiovascular system, and have some role to play in every organ of thebody. Linoleic acid is the most important member of the omega-6 familyof fatty acids. The body uses linoleic acid to synthesize an importantcarbon fatty acid, arachidonic acid, which helps maintain the structuralintegrity of cell membranes.

Linolenic acid is the most important member of the omega-3 family offatty acids. The body requires this fatty acid to make eicosapentaenoicacid (EPA) and docosahexaenoic acid (DHA). Many body tissues require EPAand DHA. DHA is especially important in the retina and in the cerebralcortex of the brain. Half of the DHA in a fetus's body accumulates inthe brain before birth, and half after birth, an indication of theimportance of fatty acids to the fetus during pregnancy and then to theyoung infant during lactation.

Successful breast-feeding requires that the mother maintain goodnutrition and adequate rest. A good, nutritional diet is needed tosupport the stamina that nursing an infant requires. Beyond this,however, a woman must consume a nutrient-rich diet to producenutrient-rich milk.

A healthy nursing mother generally makes about 25 ounces of milk eachday. To produce this milk, the mother needs to consume 650 kcaloriesabove what she would normally require for herself. Woman are advised toeat about 500 kcalories worth of extra food and let the extra fat leftover from pregnancy provide the rest. Women may not consume enough foodfor many reasons, including the desire to lose all of the weight gainedduring pregnancy. But restricting food and energy in this fashion willresult in breast milk which is lacking in nutrients, low quantities ofbreast milk or, in the worse case scenario, no breast milk at all.

According to the medical literature, a nursing mother should eat foodshigh in nutrients and drink plenty of fluid. Nutritional deprivation inthe mother generally reduces the quantity, more so than the quality, ofthe milk. So while-woman can produce milk with sufficient protein,carbohydrate, fat and minerals even if their own intake is insufficient,the quality of the breast milk is maintained at the expense of themother's own nutrient repositories. Moreover, quantities of particularvitamins, such as B6, B12, A and D, in breast milk will actually declinein response to a inadequate intakes by the mother.

Infants have different nutritional needs than those of children andadults. They require more fat and less protein than adults. Breast milkcontains high concentrations of fat-digesting enzymes that allow forhighly efficient fat absorption. Breast milk, as well as colostrum,contain the essential fatty acid linoleic acid. Understanding Nutrition,Whitney and Rolfe,6th Ed., 136-40 (1993).

Full term babies who are not fed enough linoleic acid suffer fromdermatosis and growth failure. These conditions are easily reversed whenlinoleic acid is added to the infant's diet. Fatty acid deficiency in abreast-feeding infant is a hazard of long term low fat parental dieting.The Merck Manual, 16th Ed., 968 (1992).

Methods of administering linolenic acid to lactating females have beenpreviously described. Specifically, Horrobin, U.S. Pat. No. 5,264,217,discloses methods for increasing the total fat content of milk, theessential fatty acid content of milk and the flow of milk duringlactation, or for preventing or reducing the normal decrease in milk fatcontent that occurs during prolonged lactation, by administering gammalinolenic acid, dihomo-gamma-linolenic acid or their mixture to alactating female.

Other references disclose compositions and methods that have beendeveloped for achieving fat enrichment of ruminant milk for consumptionby humans. In general, animal feed is supplemented with fatty acids. Inturn, the milk produced by the ruminants is itself rich in fatty acids.

Chalupa et al., U.S. Pat. No. 5,004,728, describe a method forincreasing milk yields in lactating ruminants. The ruminants are fedsomatotropin and salts of long chain fatty acids. The fatty acids in thefeed increases the level of long chain fatty acids in the milk producedby the ruminant. One long chain fatty acid suitable for this inventivesubject matter is linoleic acid.

Nishimura et al., U.S. Pat. No. 5,635,198, describe a granular agentcomprised by an active core coated by certain fatty acids and oils to beadministered to ruminants. This granular agent has a superior absorptionrate and results in, among other benefits, efficient lactation in theruminant.

Scott et al., U.S. Pat. No. 3,925,560, describes a feed supplement forruminants comprising fatty acids encapsulated with a protein-aldehydereaction product. These fatty acid supplements, including linoleic acid,provide high energy feed supplements for ruminants. These supplementswill result in the ruminate producing a milk very high in unsaturatedfats.

Palmquist et al., U.S. Pat. No. 4,642,317, describe a process forfeeding ruminants fatty acids in the form of their calcium salts, whichare added to feed. This process would allow dairy cows to make milk highin fats, without depleting their own fatty acid stores.

Richardson, U.S. Pat. No. 5,143,737, describes a method for themodification of ruminant food so that the ruminant will produce a milkwith modified fat. This method comprises a non-toxic food to besurrounded by an acid-sensitive nontoxic cross linking material. Animalseating this composition will make milk with a higher level ofunsaturated fats.

Furthermore, several prenatal supplements are available which providepregnant women with varying amounts of vitamins and minerals. ThePhysicians' Desk Reference describes various vitamin and mineralsupplements for use by pregnant women. For example, Nestabs® CBF,prenatal formula, available from The Fielding Company, Maryland Heights,Mo., contains 4,000 I.U. of Vitamin A, 400 I.U. of vitamin D, 30 I.U. ofvitamin E, 120 mg Of vitamin C, 1 mg of folic acid, 3 mg of thiamine, 3mg of riboflavin, 20 mg of niaclnamide, 3 mg of pyridoxine, 8 mcg ofvitamin B12, 20 mg of calcium, 100 mcg of iodine, 15 mg of zinc, and 50mg of iron per dose. NESTABS® CBF are “expressly formulated for useduring pregnancy and lactation” and

Materna® prenatal vitamin and mineral formula, available from LederleLaboratories, Pearl River, N.Y., contains 5,000 I.U. of vitamin A, 400I.U. of vitamin D, 30 I.U. of vitamin E, 120 mg of vitamin C,1 mg offolic acid, 3 mg of vitamin B13, 3.4 mg of vitamin B2, 10 mg of vitaminB6, 20 mg of niacinamide, 12 mcg of vitamin B112, 30 mcg of biotin, 10mg of pantothenic acid, 200 mg of calcium, 150 mcg of iodine, 27 mg ofiron, 25 mg of magnesium, 2 mg of copper, 25 mg of zinc, 25 mg ofchromium, 25 mg of molybdenum, 5 mg of manganese, and 20 mcg of seleniumper dose. Matema® is designed “provide vitamin and mineralssupplementation prior to conception, throughout pregnancy and during thepostnatal period for both lactating and nonlactating mothers” and isavailable in tablet form only. See Id. at 1522-3.

Enfamil® Nataling RX multivitamin and multimineral supplements,available from Mead Johnson Nutritionals, Evansville, Ind., provide 4000I.U. of vitamin A, 80 mg of vitamin C, 400 I.U. of vitamin D, 15 I.U. ofvitamin E, 1.5 mg of thiamin, 1.6 mg of riboflavin, 17 mg niacin, 4 mgof vitamin B6, 1 mg of folic acid, 2.5 mcg of vitamin B 12, 30 mcg ofbiotin, 7 mg of pantothentic acid, 200 mg of calcium, 54 mg of iron, 25mg of zinc, and 3 mg of copper-per dose. Enfamil® Natalins® RX are “tosupplement the diet during pregnancy of lactation” and are availableonly in tablet form. See Id. at 1692.

Prenate® Ultra™ prenatal vitamins, available from SanofiPharmaceuticals, New York, N.Y., contain 90 mg of elemental iron, 150mcg of iodine, 200 mg of calcium, 2 mg of copper, 25 mg of zinc, 1 mg offolic acid, 2700 I.U. of vitamin A, 400 I.U. of vitamin D3, 30 I.U. ofvitamin E, 120 mg of vitamin C, 3 mg of vitamin B 1, 304 mg of vitaminB2, 20 mg of vitamin B6, 12 mcg of vitamin B 12, 20 mg of niacinamide,and 50 mg of docusate sodium per dose. Prenate® Ultra™ is “indicated foruse in improving the nutritional status of women throughout pregnancyand in the postnatal period for both lactating and nonlactating mothers”and is only availablein tablet form. See Id. at 2802.

Niferex®-PN formula, available from Schwarz Pharma, Inc., Milwaukee,Wis., contains 60 mg of iron, 1 mg of folic acid, 50 mg of vitamin C, 3mcg of vitamin B12, 4,000 I.U. of vitamin A, 400 I.U. of vitamin D, 2.43mg of vitamin B 1, 3 mg of vitamin B2, 1.64 mg of vitamin B6, 10 mg ofniacinamide, 125 mg of calcium, and 18 mg of zinc per dose. Niferex®-PNis “indicated for prevention and/or treatment of dietary vitamin andmineral deficiencies associated with pregnancy and lactation” and isonly available in tablet form. See Physicians' Desk Reference, (53d Ed.,1999) 2916-7.

Niferex®-PN Forte formula, available from Schwarz Pharma, Inc.,Milwaukee, Wis., contains 60 mg of iron, 1 .mg of folic acid, 50 mg ofvitamin c, 3 mcg of vitamin B12, 5,000 I.U. of vitamin A, 4.00 I.U. ofvitamin D, 30 I.U. of vitamin E, 80 mg of vitamin C, 1 mg of folic acid,3 mg of vitamin B 1, 3.4 mg of vitamin B2, 4 mg of vitamin B6, 20 mg ofniacinamide, 12 mcg Of vitamin B12, 250 mg of calcium, 200 mcg of 15iodine, 10 mg of magnesium, 2 mg of copper, and 25 mg of zinc per dose.Niferex®-PN is “indicated for prevention and/or treatment of dietaryvitamin and mineral deficiencies associated with pregnancy andlactation” and is only available in tablet form. See Id. at 2917-8.

Advanced Formula Zenate® prenatal multivitamin/mineral supplement,available from Solvay Pharmaceuticals, Marietta, Ga., contains 3,000I.U. of vitamin A, 400 I.U. of vitamin D, 10 I.U. of vitamin E, 70 mg ofvitamin C, 1 mg of folic acid, 1.5 mg of vitamin B1, 1.6 mg of vitaminB2, 17 mg of niacin, 2.2 mg of vitamin B6, 2.2 of vitamin B 12, 200 mgof calcium, 175 mcg of iodine, 65 mg of iron, 100 mg of magnesium, and15 mg of zinc per dose. Advanced Formula Zenate® is “a dietary adjunctin nutritional stress associated with periconception, pregnancy andlactation” and is only available in tablet form. See Id. at 3128.

Precare® prenatal multi-vitamin/mineral formula, available from UCBPharma, Inc., Smyrna, Ga., contains 50 mg of vitamin C, 250 mg ofcalcium, 40 mg of iron, 6 mcg of vitamin D, 3.5 mg of vitamin E, 2 mg ofvitamin B6, 1 mg of folic acid, 50 mg of magnesium, 15 mg of zinc and 2mg of copper per dose. Precare® “is indicated to provide vitamin andmineral supplementation throughout pregnancy and during the postnatalperiod-for both lactating and nonlactating mothers and is available onlyin caplet form. See Id. at 3163.

Natafort® prenatal multivitamin, available from Warner Chilcott,Rockaway, N.J., contains 1,000 I.U. pf vitamin A, 400 I.U. of vitaminD3, 11 I.U. of vitamin E, 120 mg of vitamin C, 1 mg of folic acid, 2 mgof thiamine mononitrate, 3 mg of riboflavin, 20 mg of niacinamide, 10 mgof vitamin B6, 12 mcg of vitamin B 12, and 60 mg of iron per dose.Natafort® is designed “to provide vitamin and mineral supplementationthroughout pregnancy and during the postnatal period, for both thelactating and nonilactating mother” and is only available in tabletform. See Id. at 3212.

However, none of the above formulations provide women with essentialfatty acids in amounts and proportions necessary to optimize infantneurological development. Further, the prenatal nutritional supplementscontaining vitamins and minerals are entirely lacking in essential fattyacids. In the case of the enriched ruminant milk, while this milk may bea good source of fatty acids for adults, ruminant milk is notrecommended for infants because even supplemented formula cannot matchthe immunological benefits of breast milk.

Therefore, there remains a need for a nutritional formulation whichoptimizes infant neurological development. It is also desirable to havenutritional formulations which prevent a woman's stores of fatty acidsfrom becoming depleted during lactation. There is also a particular needfor nutritional formulation which provide essential fatty acids inoptimal ratios and amounts, along with required vitamins and minerals.Moreover, it is desirable to have formulations and methods which preparea woman's body for the stresses imposed by lactation.

SUMMARY OF INVENTION

The methods of the present inventive subject matter for administeringcompositions containing essential fatty acids for use by pregnant and/orlactating women overcome the deficiencies of currently availablemethods.

In one embodiment of the inventive subject matter, a method foradministering essential fatty acids comprises administering acomposition of essential fatty acids to a pregnant or lactating woman,wherein at least two of the essential fatty acids are selected from thegroup consisting of linolenic acid, linoleic acid, arachidonic acid,eicosapentaenoic acid, docosahexaenoic acid, an omega-3 fatty acid, anomega-6 fatty acid and mixtures thereof; wherein the essential fattyacids in the composition are present in an amount ranging from about 100mg to about 1,000 mg per 55 kg of body weight of the pregnant orlactating woman; and wherein the essential fatty acids maximize theweight of a member selected from the group consisting of an embryo, afetus or a multiple gestation.

In another embodiment of the inventive subject matter, a method “foradministering essential fatty acids comprises administering acomposition of essential fatty acids to the pregnant or lactating woman,wherein at least two of the essential fatty acids are selected from thegroup consisting of linolenic acid, linoleic acid, arachidonic acid,eicosapentaenoic acid, docsahexaenoic acid, an omega-3 fatty acid, anomega-6 fatty acid, and mixtures thereof;

wherein the essential fatty acids in the gomposition are present in anamount ranging from about 100 mg to about 1,000 mg per 55 kg of bodyweight of the pregnant or lactatingwoman; and wherein the essentialfatty acids optimize the length of gestation of a member selected fromthe group consisting of an embryo, a fetus or a multiple gestation.

In yet another embodiment of the inventive subject matter, a method foradministering essential fatty acids comprises administering acomposition of essential fatty acids to a woman, wherein at least two ofthe essential fatty acids are selected from the group consisting oflinolenic acid, linoleic acid, arachidonic acid, eicosapentaenoic acid,docsahexaenoic acid, an omega-3 fatty acid, an omega-6 fatty acid, andmixtures thereof; wherein the essential fatty acids in the compositionare present in an amount ranging from about 100 mg to about 1,000 mg per55 kg of body weight of the woman; and wherein the essential fatty acidstreat essential fatty acid deficiencies in the woman.

DETAILED DESCRIPTION

As used herein, “nutritional stores” refers to the levels of vitamins,minerals and other nutrients which will be available for use by themother, developing embryo, fetus and newborn infant.

“Nutritional status” refers to the presence or absence of any nutrientdeficiency, or in other words, the extent to which physiologicalnutrient demands are being satisfied such that deficiency is avoided.

“Optimize neurological development” refers to attainment of the highestdegree of neurological development possible through natural processeswithout the use of any unnatural substances or procedures, such asdrugs, surgery and the like.

“Biologically active substance” refers to any substance or substancescomprising a drug, active therapeutic substance, metabolite, medicament,vitamin, or mineral, any substance used for treatment, prevention,diagnosis, cure or mitigation of disease or illness, any substance whichaffects anatomical structure or physiological function, or any substancewhich alters the impact of external influences on an animal, ormetabolite thereof, and as used herein, encompasses the terms “activesubstance,” “therapeutic substance,” “agent,” “active agent,” “activetherapeutic agent,” “drug,” “medication,” “medicine,” “medicant,” andother such similar terms.

“Specific physiological needs” refers to the unique requirements forcertain levels of certain nutrients by one class of persons, such aslactating women, pregnant women, etc., as distinguished from otherclasses.

“Biologically-acceptable” refers to being safe for human consumption.

“Neonate” refers to the offspring of a female mammal that is nursed bysaid female mammal and has not yet been weaned.

“Essential fatty acids” or EFAs may refer to any fatty acid that may beutilized by the body, and included, without limitation, chemical chainsof carbon, hydrogen, and oxygen atoms that are part of a fat (lipid),are a major component of triglycerides, which may be classified aseither saturated, polyunsaturated, or monounsaturated, and may be foundin nature or produced synthetically. They may include without limitationcholesterol, prostaglandins, lecithin, choline, inositol, conjugatedlinolenic acid, myristic acid, palmitic acid, stearic acid, oleic acid,alpha-linolenic acid, eicosapentaenoic acid, docosapentaenoic acid,docosahexanoic acid, linolenic acid, gamma-linolenic acid, linoleicacid, omega 3 fatty acids, omega 6 fatty acids, omega 9 fatty acids,polyunsaturated fatty acids, long-chained polyunsaturated fatty acids,arachidonic acid, monounsaturated fatty acids, precursors of fattyacids, and derivatives of fatty acids.

The compositions and methods of the present inventive subject matterprovide several specific new and unexpected benefits. First, theformulations may improve the nutritional status of a woman prior toconception. Second, the formulations may increase fetal birth weight.Third, the formulations and methods may increase the length ofgestation. Fourth, the formulations ensure that both the mother and herinfant or infants are provided with adequate energy during the period oflactation. Fifth, the formulations allow the mother to maintain adequatefatty acid stores for both her own use and for incorporation into herbreast milk as her supplies are depleted during lactation. Sixth, thefatty acids optimize the overall development and neurologicaldevelopment of the infant consuming the breast milk. Fourthly, whenadministered prior to lactation, the present compositions prepare womenfor the increased physiological demands and stresses to be placed upontheir bodies. Finally, the present compositions help women recover frompregnancy and lactation and prepare women for additional pregnancies andsubsequent lactation.

Thus, the inventive subject matter provides for methods and compositionsdesigned to be administered to a woman prior to the onset of pregnancyfor the purpose of improving nutritional status prior to conception;methods and compositions designed to be administered during pregnancy toprovide adequate nutrition for the pregnant woman and the developingembryo, embryos, fetus or fetuses; methods and compositions foradministration during pregnancy to provide adequate nutrition to thepregnant woman and the developing embryo, embryos, fetus or fetuses forthe purpose of increasing or maximizing the length of gestation and/orincreasing or maximizing birth weight; and methods and compositions forthe purpose of both enriching the woman's breast milk for the benefit ofthe child or children and also to directly benefit the woman. In fact,in some cases, the formulations may allow a woman to breast-feed herinfant where, in the absence of taking the present composition,breast-feeding would have been either unsafe or outright impossible.Infants undergoing gestation while the mother's diet is modifiedaccording to the methods and compositions of the present invention, asdescribed herein, may undergo advantageous in utero development andincrease gestational duration. Furthermore, infants consuming theenriched breast milk, as described herein, will experience optimalneurological development. Further still, the present methods andcompositions will help a post-partum woman to recover from her pregnancyand labor quickly and efficiently by providing her with the fatty acidslost in pregnancy and lactation. In addition, the present methods andcompositions will place a woman in optimal condition for an additionalpregnancy and the lactation that will follow by helping her increase hernutritional stores of critical nutritional compounds.

The present inventive subject matter is based, in part, on the discoverythat when compositions having certain fatty acids, in certain amountsand proportions to one another, are administered to women prior to andduring pregnancy and prior to and during lactation, embryos and fetusesin utero contemporaneously with said administration may experienceincrease in birth weight and length of gestation, as well as maximizeddevelopment and that infants who consume the breast milk of said womenwill achieve optimized neurological development. In particular,supplementing the mother's diet with certain fatty acids for a periodbeginning at least ten weeks after conception, preferably at least tenweeks prior to conception and continuing through out the pregnancy andlactation period, and either ending when lactation ceases or beingcontinued as a supplement will not only optimize the neural developmentof the breast-feeding infant, but also ensure that the mother hasadequate essential fatty acids for her own use. The fatty acidsupplement may also further contain vitamins and minerals to conferadded health benefits to the infant or infants and mother. In additionto benefiting a developing human embryo or fetus, as well as abreast-feeding human infant, the present invention can also benefit theembryo, fetus and/or spring of non-human mammals wherein the mothermammal's diet is supplemented according to the methods and compositionsof the present invention before, during or after pregnancy and saidoffspring are nursed by their mothers. The methods and compositions ofthe present invention could be administered to a mammal in animal feed,pill form, or other appropriate dosage forms to such mammals withoutlimitation.

Without being limited by theory, the present compositions maintain andstabilize fatty acid levels in the blood before, during and afterpregnancy and lactation. Maintenance and stabilization of fatty acidlevels in the blood may serve beneficially in numerous bodily functionsof both the mother and the embryo or fetus, such as, for exampleimmunological development, immunoregulation and immunoresponse,production and maintenance of appropriate levels of various hormonesbeneficial to pregnancy, birth and lactation, such as for example,prostaglandin. Prostaglandin may serve to increase the duration ofgestation. Additionally, maintenance and stabilization of EFA levels inthe pregnant mother serves to maximize the development of the embryo orfetus neurologically and physically. Further, maintenance of fatty acidlevels in the body of the mother may stimulate the production of breastmilk which is enriched with the EFAs in amounts which optimize infantneurological development. These methods and compositions achieve suchbenefit to both woman who is planning to conceive or is pregnant and theenrichment of the breast milk through one or more natural biologicalpathways. For example, the arachidonic acid cascade may play asignificant role in the enrichment of the breast milk Specifically, inthe arachidonic acid cascade, linoleic acid is converted first togamma-linolenic acid and then to further metabolites such asdihomo-gamma-linolenic acid and arachidonic acid which are precursors of1 and 2 series prostaglandin respectively, as shown in the outlinebelow:

The present composition contains at least two fatty acid compounds. Thefirst fatty acid compound is selected from the group consisting of alinoleic acid compound, a linolenic acid compound, derivatives thereofand combinations thereof. The second fatty acid compound is selectedfrom the group consisting of a docosahexaenoic acid compound, an omega-3fatty acid compound, an omega-2 fatty acid compound, derivatives thereofand combinations thereof. Moreover, when the first fatty acid compoundis linolenic acid or a derivative thereof and the second fatty acidcompound is an omega-3 fatty acid, said omega-3 fatty acid is notlinolenic acid or a derivative thereof. It is also preferred that whenthe first fatty acid compound is linoleic acid or a derivative thereofand the second fatty acid compound is an omega-2 fatty acid, saidomega-2 fatty acid is not linoleic acid or a derivative thereof.

The two fatty acid compounds are present in the composition in criticalproportions to one another. Preferably, the weight ratio of the firstfatty acid to the second fatty acid is about 1:0.001 to 50. Morepreferably, the weight ratio of the first fatty acid compound to thesecond fatty acid compound is about 1:0.i to 10. Even more preferably,the weight ratio of the first fatty acid compound to the second fattyacid compound is about 1:0.9 to 2.5. Most preferably, the weight ratioof the first fatty acid compound to the second fatty acid compound isabout 1:1 to 2.

The fatty acids of the present inventive subject matter may be used assuch or as biologically acceptable and physiologically equivalentderivatives as, for example, detailed later herein. Reference to any ofthe fatty acids including reference in the claims is to be taken asincluding reference to the acids when in the form of such derivatives.Equivalence is demonstrated by entry into the biosynthetic pathways ofthe body as evidenced by effects corresponding to those of the acidsthemselves or their natural glyceride esters. Thus, indirectidentification of useful derivatives is by their having the valuableeffect in the body of the fatty acid itself, but conversion, forexample, of gamma-linolenic acid to dihomo-gamma-linolenic acid and onto arachidonic acid can be shown directly by gas chromatographicanalysis of concentrations in blood, body fat, or other tissue bystandard techniques, well known to persons of ordinary skill in the artto which the present inventive subject matter pertains.

Derivatives of linoleic acid, as used in the present inventive subjectmatter, include, without limitation, salts of linoleic acid, alkalinesalts of linoleic acid, esters of linoleic acid, and combinationsthereof. Derivatives of linolenic acid, as used in the present inventivesubject matter, include, without limitation, salts of linolenic acid,alkaline salts of linolenic acid, esters of linoleic acid, andcombinations thereof. The salts and alkaline salts herein refer to thoseregularly used organic or inorganic salts which are acceptable forpharmaceutical use. Non-limiting exemplary linolenic acids includegamma-linoleic acid and dihomo-gamma-linolenic acid.

The fatty acids of the present inventive subject matter may be from anysource, including, without limitation, natural or synthetic oils, fats,waxes or combinations thereof. Moreover, the fatty acids herein may bederived, without limitation, from non-hydrogenated oils, partiallyhydrogenated oils, fully hydrogenated oils or combinations thereof.Non-limiting ehemplary sources of fatty acids include seed oil, fish ormarine oil, canola oil, vegetable oil, safflower oil, sunflower oil,nasturtium seed oil, mustard seed oil, olive oil, sesame oil, soybeanoil corn oil, peanut oil, cottonseed oil, rice bran oil, babassu nutoil, palm oil low erucic rapeseed oil palm kernel oil, lupin oil coconutoil, flaxseed oil, evening primrose oil, jojoba, tallow, beef tallow,butter, chicken fat, lard, dairy butterfat, shea butter or combinationsthereof. Specific non-limiting exemplary fish or marine oil sourcesinclude shellfish oil, tuna oil, mackerel oil, salmon oil, menhaden,anchovy, herring, trout, sardines or combinations thereof. Preferably,the source of the fatty acids is fish or marine oil, soybean oil orflaxseed oil.

The present composition may optionally contain additional vitamins andbiologically-acceptable minerals. Non-limiting exemplary vitamins andbiologically acceptable minerals and their derivatives thereof forinclusion in the present compositions include vitamin A, B vitamins,vitamin C, vitamin D, vitamin E, vitamin K, folic acid, iron, calcium,magnesium, potassium, copper, chromium, zinc, molybdenum, iodine, boron,selenium, manganese, derivatives thereof or combinations thereof. Thesevitamins and minerals may be from any source or combination of sources,without limitation. Non-limiting exemplary B vitamins include, withoutlimitation, thiamine, niacinamide, pyridoxine, riboflavin,cyanocobalamin, biotin, pantothenic acid or combinations thereof.

When vitamin C is present in the composition of the present inventivesubject matter, it is preferably present in an amount ranging from about10 mg to about 500 mg. More preferably, the vitamin C is present in anamount ranging from about 25 mg to about 400 mg. Even more preferably,the vitamin C is present an immediate release form in an amount rangingfrom about 25 mg to about 50 mg. Most preferably, the vitamin C ispresent in a controlled release form in an amount ranging from about 250mg to about 500 mg.

When vitamin E is present in the composition of the present inventivesubject matter, it is preferably present in an amount ranging from about5 mg to about 500 mg. More preferably, the vitamin E is present in anamount ranging from about 10 mg to about 400 mg. Even morepreferably,.the vitamin E is present in a controlled release form in anamount ranging from about 250 mg to about 400 mg. Most preferably, thevitamin E is present in an immediate release form in an amount rangingfrom about 10 mg to about 50 mg.

Vitamin B6 may also be present in the composition of the presentinventive subject matter. Vitamin B6 is preferably present in an amountranging from about 10 mg to about 200 mg. More preferably, vitamin B6 ispresent in an amount ranging from about 20 mg to about 125 mg. Even morepreferably, vitamin B6 is present in an immediate release form in anamount ranging from 20 mg to about 50 mg. Most preferably, vitamin B6 ispresent in a controlled release form in an amount ranging from 50 mg toabout 125 mg.

Folic acid may also be incorporated into the composition of the presentinventive subject matter. When folic acid is present in the composition,it is referably present in an amount ranging from about 0.1 mg to about4 mg and may be in either immediate release or controlled release form.More preferably, folic acid is present in an immediate release form inan amount ranging from about 0.i mg to about 2 mg. Even more preferably,folic acid is present in a controlled release form in an amount rangingfrom about 1.5 mg to about 3 mg.

Calcium is preferably present in the composition of the presentinventive subject matter in an amount ranging from about 100 mg to about2,500 mg. More preferably, calcium is present in an amount ranging fromabout 100 mg to about 1,000 mg. Even more preferably, calcium is presentin an immediate release form in an amount ranging from about 100 mg toabout 500 mg. Most preferably, calcium is present in a controlledrelease form in an amount ranging from about 500 mg to about 2,000 mg.

Magnesium is preferably present in the composition of the presentinventive subject matter in an amount ranging from about 25 mg to about400 mg. More preferably, magnesium is present in the composition of thepresent inventive subject matter in an immediate release form in anamount ranging from about 25 mg to about 100 mg. Even more preferably,magnesium is present in the composition of the present inventive subjectmatter in a controlled release form in an amount ranging from about 100mg to about 400 mg.

The composition of the present inventive subject matter may also includeone or more biologically active substance. The biologically activesubstances incorporated into the present inventive subject matter arenonteratogenic to protect the unborn fetus. For example, withoutlimitation, the biologically active substance may be a lactogencompound, a derivative of a lactogen compound or combinations thereof.Derivatives of lactogen compounds include, without limitation, salts oflactogen compounds, alkaline salts of lactogen compounds, esters oflactogen compounds and combinations thereof.

Various additives may be incorporated into the present composition.Optional additives of the present composition include, withoutlimitation, starches, sugars, fats, antioxidants, amino acids, proteins,derivatives thereof or combinations thereof.

It is also possible in the nutritional composition of the presentinventive subject matter for the dosage form to combine various forms ofrelease, which include, without limitation, immediate release, extendedrelease, pulse release, variable release, controlled release, timedrelease, sustained release, delayed release, long acting, andcombinations thereof. The ability to obtain immediate release, extendedrelease, pulse release, variable release, controlled release, timedrelease, sustained release, delayed release, long acting characteristicsand combinations thereof is performed using well known procedures andtechniques available to the ordinary artisan. Each of these specifictechniques or procedures for obtaining the release characteristics doesnot constitute an inventive aspect of this inventive subject matter allof which procedures are well known to those of ordinary skill in theart. As used herein, a “controlled release form” means any form havingat least one component formulated for controlled release. As usedherein, “immediate release form” means any form having all itscomponents formulated for immediate release.

Any biologically-acceptable dosage form, and combinations thereof, arecontemplated by the inventive subject matter. Examples of such dosageforms include, without limitation, chewable. tablets, quick dissolvetablets, effervescent tablets, reconstitutable powders, elixirs,liquids, solutions, suspensions, emulsions, tablets, multi-layertablets, bi-layer tablets, capsules, soft gelatin capsules, hard gelatincapsules, caplets, lozenges, chewable lozenges, beads, powders,granules, particles microparticles, dispersible granules, cachetsdouches, suppositories, creams, topicals, inhalants aerosol inhalants,patches, particle inhalants implants, depot implants, ingestibles,injectables infusions, health bars, confections, animal feeds cereals,cereal coatings, foods, nutritive foods functional foods andcombinations thereof. The preparation of the above dosage forms are wellknown to persons of ordinary skill in the art.

The following procedures represent, without limitation, of acceptablemethods of preparing formulations falling within the scope of theinventive subject matter. For example, animal feed may be by methodswell known to persons of ordinary skill in the art. Animal feeds may beprepared by mixing the formulation with binding ingredients to form aplastic mass. The mass is then extruded under high pressure to formtubular (or “spaghetti-like”) structures that are cut to pellet size anddried.

Quick dissolve tablets may be prepared, for example, without limitation,by mixing the formulation with agents such as sugars and cellulosederivatives, which promote dissolution or disintegration of theresultant tablet after oral administration, usually within 30 seconds.

Cereal coatings may be prepared, for example, without limitation, bypassing the cereal formulation, after it has been formed into pellets,flakes, or other geometric shapes, tinder a precision spray coatingdevice to deposit a film of active ingredients, plus excipients onto thesurface of the formed elements. The units thus treated are then dried toform a cereal coating.

For example, nutrition or health bars may be prepared, withoutlimitation, by mixing the formulation plus excipients (e.g., binders,fillers, flavors, colors, etc.) to a plastic mass consistency. The massis then either extended or molded to form “candy bar” shapes that arethen dried or allowed to solidify to form the final product.

Soft gel or soft gelatin capsules may be prepared, for example, withoutlimitation, by dispersing the formulation in an appropriate vehicle(vegetable oils are commonly used) to form a high viscosity mixture.This mixture is then encapsulated with a gelatin based film usingtechnology and machinery known to those in the soft gel industry. Theindustrial units so formed are then dried to constant weight.

Chewable tablets, for example, without limitation, may be prepared bymixing the formulations with excipients designed to form a relativelysoft, flavored, tablet dosage form that is intended to be chewed ratherthan swallowed. Conventional tablet machinery and procedures, that isboth direct compression and granulation, i.e., or slugging, beforecompression, can be utilized. Those individuals involved inpharmaceutical solid dosage form production are well versed in theprocesses and the machinery used as the chewable, dosage form is a verycommon dosage form in the pharmaceutical industry.

Film coated tablets, for example, without limitation, may be prepared bycoating tablets using techniques such as rotating pan coating methods orair suspension methods to deposit a contiguous film layer on a tablet.This procedure is often done to improve the aesthetic appearance oftablets, but may also be done to improve the swallowing of tablets, orto mask an obnoxious odor or taste, or to improve to usual properties ofan unsightly uncoated tablet.

Compressed tablets, for example, without limitation, may be prepared bymixing the formulation with excipients intended to add binding qualitiesto disintegration qualities. The mixture is either directly compressedor granulated then compressed using methods and machinery quite wellknown to those in the industry. The resultant compressed tablet dosageunits are then packaged according to market need, i.e., unit dose,roils, bulk bottles, blister packs, etc.

The present inventive subject matter contemplates nutritionalcompositions formulated for administration by any route, includingwithout limitation, oral, buccal, sublingual, rectal, parenteral,topical, inhalational, injectable and transdermal. The physicochemicalproperties of nutritional compositions, their formulations, and theroutes of administration are important in absorption. Absorption refersto the process of nutritional composition movement from the site ofadministration toward the systemic circulation. Most orally administerednutritional compositions are in the form of tablets or capsulesprimarily for convenience, economy, stability, and patient acceptance.They must disintegrate and dissolve before absorption can occur. Usingthe present inventive subject matter with any of the above routes ofadministration or dosage forms is performed using well known proceduresand techniques available to the ordinary skilled artisan.

The present inventive subject matter contemplates the use ofbiologically-acceptable carriers which may be prepared from a wide rangeof materials, without being limited thereto, such materials includediluents, binders and adhesives, lubricants, plasticizers,disintegrants, colorants, bulking substances, flavorings, sweeteners andmiscellaneous materials such as buffers and adsorbents in order toprepare a particular medicated composition.

Binders may be selected from a wide range of materials such ashydroxypropylmethylcellulose, ethylcellulose, or other suitablecellulose derivatives, povidone, acrylic and methacrylic acidco-polymers, pharmaceutical glaze, gums, milk derivatives, such as whey,starches, and derivatives, as well as other conventional binders wellknown to persons skilled in the art. Exemplary non-limiting solvents arewater, ethanol, isopropyl alcohol, methylene chloride or mixtures andcombinations thereof. Exemplary non-limiting bulking substances includesugar, lactose, gelatin, starch, and silicon dioxide.

The plasticizers used in the dissolution modifying system are preferablypreviously dissolved in an organic solvent and added in solution form.Preferred plasticizers may be selected from the group consisting ofdiethyl phthalate, diethyl sebacate, triethyl citrate, cronotic acid,propylene glycol, butyl phthalate, dibutyl sebacate, caster oil andmixtures thereof, without limitation. As is evident, the plasticizersmay be hydrophobic as well as hydrophilic in nature. Water-insolublehydrophobic substances, such as diethyl phthalate, diethyl sebacate andcaster oil are used to delay the release of water-soluble vitamins, suchas vitamin B6 and vitamin C. In contrast, hydrophilic plasticizers areused when water-insoluble vitamins are employed which aid in dissolvingthe encapsulated film, making channels in the surface, which aid innutritional composition release.

The composition of the present inventive subject matter may beadministered in a partial, i.e., fractional dose, one or more timesduring a 24 hour period, a single dose during a 24 hour period of time,a double dose during a 24 hour period of time, or more than a doubledose during a 24 hour period of time. Fractional, double or othermultiple doses may be taken simultaneously or at different times duringthe 24 hour period.

The compositions of the present invention are intended for use by humansand other mammals. The dosages are adjusted according to body weight andthus may be set forth herein on a per body weight basis. For example, ifthe formula specifies a range of about 10-1000 mg for a 55 kgindividual, that range would be adjusted for a 35 kg individual to about6.3-63 mg (e.g., the lower range limit=(35 kg/55 kg)*10 mg=6.3 mg).Decimal amounts may be rounded to the nearest whole number. In the abovemanner the present compositions may thus be adapted to be suitable forany individual, including any mammal, regardless of its size.

The present methods and compositions are adapted to meet the specificphysiological needs of a woman planning to conceive a woman who ispregnant, either with a single or multiple pregnancy, and/or abreast-feeding mother. For example, the formulations may focus onspecial nutritional needs of the mother that are not generally addressedin prenatal supplements, such as essential fatty acids, iron andcalcium, without limitation. The iron and calcium, when present, areprovided in amounts to optimize nutritional benefit to the mother, whileminimizing unpleasant side effects which may accompany overly largedoses. The formulation can be further tailored based upon the specificneeds, genetic predispositions or identified deficiencies of women.Moreover, the present composition can be used as one component of aprescribed therapy.

Biologically-acceptable calcium compounds include, but are not limitedto, any of the well known calcium supplements, such as calciumcarbonate, calcium sulfate, calcium oxide, calcium hydroxide, calciumapatite, calcium citrate-mahate, bone meal, oyster shell, calciumgluconate, calcium lactate, calcium phosphate, calcium levulinate, andthe like.

Biologically-acceptable magnesium compounds which may be incorporatedinto the present inventive subject matter include, but are not limitedto, magnesium stearate, magnesium carbonate, magnesium oxide, magnesiumhydroxide and magnesium sulfate.

The compositions of the inventive subject matter may be provided in ablister pack or other such pharmaceutical package, without limitation.Further, the compositions of the present inventive subject matter mayfurther include or be accompanied by indicia allowing women to identifythe compositions as products for persons planning to or currentlybreast-feeding their infants. The indicia may further additionallyinclude an indication of the above specified time periods for using saidcompositions.

The methods and compositions of the present inventive subject matter arepreferably administered during a period commencing no later than atleast the tenth week of pregnancy. Preferably, the methods andcompositions are administered beginning about ten weeks prior topregnancy. Also preferably, the methods and compositions areadministered during a period of time commencing on about the tenth weekof pregnancy and continuing through to completion of breast-feeding orcontinuing on as a nutritional supplement for the mother.

The present inventive subject matter includes methods for; improvingand/or maximizing a woman's nutritional status prior to pregnancy;increasing and/or improving the length of gestation; improving and/ormaximizing the development of an embryo, embryos fetus or fetuses; andenriching the breast milk of women to optimize neurological developmentof infant's breast-fed by said women. The methods include administrationof the present composition to women during a critical period. Thecritical period of administration is the period commencing at least atabout the tenth week of pregnancy and terminating at the conclusion ofbreast-feeding or continuing on as a nutritional supplement for themother. The methods include administering the compositions as early asthree months prior to conception.

The present compositions and methods may increase lactogenesis or thequantity of breast milk produced during lactation. Further, thecompositions and methods may prevent or at least minimize fatty aciddeficiency in lactating women. The quality of breast milk may also beimproved by the compositions and methods. Moreover, the duration of theperiod of lactation may be extended by the present compositions andmethods. Thus, women who would have difficulty breast-feeding for morethan four weeks after pregnancy when not taking the present composition,could breast-feed for more than four weeks after pregnancy when takingthe present composition.

The foregoing is considered as illustrative only of the principles ofthe inventive subject matter. Further, since numerous modifications andchanges will readily occur to those skilled in the art, it is notdesired to limit the inventive subject matter to the exact constructionand operation shown and described, and accordingly all suitablemodifications and equivalents may be resorted to, falling within thescope of the inventive subject matter.

The following examples are illustrative of preferred embodiments of theinventive subject matter and are not to be construed as limiting theinventive subject matter thereto. All percentages are based on thepercent by weight of the final delivery system or formulation preparedunless otherwise indicated and all totals equal 100% by weight.

EXAMPLES Example 1

The following formulations are used to prepare compositions foradministration to women prior to and during pregnancy and lactation:Component (in mg unless otherwise indicated) Formula I Formula IIFormula III Linoleic Acid 10 100 20 Linolenic Acid 10 100 20 Omega-3Fatty Acid 10 20 50 Omega-2 Fatty Acid — — 50 Vitamin C 25 400 700Vitamin E (I.U.) 10 400 200 Vitamin A (I.U.) 2700 2700 2700 Vitamin D3(I.U.) 400 400 400 Vitamin B6 20 125 20 Folic Acid 2.0 2.0 2.0 Iron 9090 90 Calcium 2500 400 1000 Microcrystalline 200 200 200 CelluloseStarch 200 200 200 Silicon Dioxide 3 5 5 Magnesium Stearate 10 12 15

Example 2

The following compositions are used to prepare controlled releaseproducts for administration to women prior to and during pregnancy andlactation:

Example 3

Component (in mg unless otherwise Controlled Release Controlled Releaseindicated) Formula A Formula B Linoleic Acid  20  20 Linolenic Acid  20 20 Omega-3 Fatty Acid  50  50 Omega-2 Fatty Acid  50  50 Vitamin C  250400 Vitamin E (I.U.)  200 400 Vitamin A (I.U.) 2700 — Vitamin D3 (I.U.) 400 — Vitamin B6  125* 125* Folic Acid   2.5*  2.5* Iron  90* — Calcium 500 100 Microcrystalline Cellulose  200 200 Starch  200 200 SiliconDioxide   5  1 Magnesium Stearate  15  15 Ethylcellulose  60  60 FolicAcid —  1 Magnesium —  25*Formulated for controlled release

Example 3

The following compositions are used to prepare products foradministration to women prior to and during pregnancy and lactation:Component IV V VI VII VIII IX Linoleic Acid 10 100 20 10 100 20Linolenic Acid 10 100 20 10 100 20 Omega-3 Fatty 10 10 50 10 10 50 AcidOmega-2 Fatty — — 50 — — 50 Acid Vitamin B6 20 125 20 20 125 20 FolicAcid 0.1 3 1 0.1 3 1 Calcium 100 400 1000 100 1000 1000 Magnesium — — —25 400 25 Vitamin C — — — 25 400 400 Vitamin E (I.U.) — — — 10 400 400Microcrystalline 100 100 200 100 100 100 Cellulose Starch 100 100 200100 100 100 Silicon Dioxide 0.3 0.7 1 0.3 1 1 Magnesium 3 7 15 3 15 15Stearate Lactose 100 — — 100 — — Ethylcellulose — — — — — —

The above components are in mg unless otherwise indicated. Tabletsincorporating the above formulations are prepared using conventionalmethods and materials known in the pharmaceutical art. The resultingnutritional compositions were recovered and stored for future use.

Example 4

The following compositions are used to prepare products foradministration to women prior to and during pregnancy and lactation:Component IV V VI VII VIII IX Linoleic Acid — 100 — 10 100 20 LinolenicAcid — 100 — 10 100 20 Omega-3 Fatty 10 10 50 10 10 50 Acid Omega-2Fatty — — 50 — — 50 Acid Vitamin B6 20 125 20 20 125 20 Folic Acid 0.1 31 0.1 3 1 Calcium 100 400 1000 100 1000 1000 Magnesium — — — 25 400 25Vitamin C — — — 25 400 400 Vitamin E (I.U.) — — — 10 400 400Microcrystalline 100 100 200 100 100 100 Cellulose Starch 100 100 200100 100 100 Silicon Dioxide 0.3 0.7 1 0.3 1 1 Magnesium 3 7 15 3 15 15Stearate Lactose 100 — — 100 — — Ethylcellulose — — — — — —

The above components are in mg unless otherwise indicated. Tabletsincorporating the above formulations are prepared using conventionalmethods and materials known in the pharmaceutical art. The resultingnutritional compositions were recovered and stored for future use.

Example 5

A soft gelatin supplement may be prepared, by first combining mineraloil and soybean oil in a first vessel and blending it to form a uniformoil mixture, heating the oil mixture to 45 degrees Celsius, and thenadding propylene glycol. In a second vessel preheated to 70 degreesCelsius, yellow beeswax and soybean oil are added and blended until auniform wax mixture is formed. The wax mixture is cooled to 35 degreesCelsius and then added to the oil mixture. To this combined oil and waxmixture, folic acid, vitamin B6, iron, magnesium, and calcium are thenadded and blended together to form a uniform biologically activemixture. The mixture is then cooled to 30 degrees Celsius to form aviscous biologically active core composition, after which time thecomposition is ready for encapsulation in a soft gelatin shell.

A soft gelatin shell is prepared by heating purified water in a suitablevessel and then adding gelatin. This water gelatin mixture is mixeduntil the gelatin is fully dissolved, and then glycerin, preservatives,one or more flavors, and one or more colorants are added. This gelatinmixture is blended well and cooled. The shells are then filled with thecore composition and formed in accordance with soft gelatin techniquescommonly used and well known to persons of skill in the art.

The inventive subject matter being thus described, it will be apparentthat the same may be varied in many ways. Such variations are not to beregarded as a departure, from the spirit and scope of the inventivesubject matter, and all such modifications are intended to be within thescope of the appended claims.

1. A composition for supplementing the diet, the composition comprising:a. a first fatty acid; and b. DHA present in a quantity such that thetotal amount of said first fatty acid and said DHA is from about 10 mgto about 1000 mg.
 2. A composition for administration to a pregnant orlactating woman, the composition comprising: a. a first fatty acid; andb. DHA present in a quantity such that the total amount of said firstfatty acid and said DHA is from about 10 mg to about 1000 mg.
 3. Amethod for administering essential fatty acids, which comprises: a.administering a first fatty acid; and b. administering DHA present in aquantity such that the total amount of said first fatty acid and saidDHA is from about 10 mg to about 1000 mg.
 4. A method for administeringessential fatty acids to pregnant or lactating women, which comprises:a. administering a first fatty acid; and b. administering DHA present ina quantity such that the total amount of said first fatty acid and saidDHA is from about 10 mg to about 1000 mg.
 5. The composition of claim 1,wherein the ratio of the amount of said first fatty acid to said DHA isfrom about 1:0.001 to about 1:50.
 6. The composition of claim 2, whereinthe ratio of the amount of said first fatty acid to said DHA is fromabout 1:0.001 to about 1:50.
 7. The method of claim 3, wherein the ratioof the amount of said first fatty acid to said DHA is from about 1:0.001to about 1:50.
 8. The method of claim 4, wherein the ratio of the amountof said first fatty acid to said DHA is from about 1:0.001 to about1:50.